JP2008515889A5 - - Google Patents

Download PDF

Info

Publication number
JP2008515889A5
JP2008515889A5 JP2007535700A JP2007535700A JP2008515889A5 JP 2008515889 A5 JP2008515889 A5 JP 2008515889A5 JP 2007535700 A JP2007535700 A JP 2007535700A JP 2007535700 A JP2007535700 A JP 2007535700A JP 2008515889 A5 JP2008515889 A5 JP 2008515889A5
Authority
JP
Japan
Prior art keywords
seq
xaa
conjugate molecule
cys
sabm
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2007535700A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008515889A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2005/033952 external-priority patent/WO2006041641A2/en
Publication of JP2008515889A publication Critical patent/JP2008515889A/ja
Publication of JP2008515889A5 publication Critical patent/JP2008515889A5/ja
Withdrawn legal-status Critical Current

Links

JP2007535700A 2004-10-05 2005-09-22 毒性の低下した治療剤 Withdrawn JP2008515889A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US61650704P 2004-10-05 2004-10-05
US64153405P 2005-01-05 2005-01-05
PCT/US2005/033952 WO2006041641A2 (en) 2004-10-05 2005-09-22 Therapeutic agents with decreased toxicity

Publications (2)

Publication Number Publication Date
JP2008515889A JP2008515889A (ja) 2008-05-15
JP2008515889A5 true JP2008515889A5 (enExample) 2008-11-13

Family

ID=36051453

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007535700A Withdrawn JP2008515889A (ja) 2004-10-05 2005-09-22 毒性の低下した治療剤

Country Status (11)

Country Link
US (2) US20060073152A1 (enExample)
EP (1) EP1796718A2 (enExample)
JP (1) JP2008515889A (enExample)
KR (1) KR20070073886A (enExample)
AU (1) AU2005294723A1 (enExample)
BR (1) BRPI0516577A (enExample)
CA (1) CA2583137A1 (enExample)
IL (1) IL182261A0 (enExample)
MX (1) MX2007003907A (enExample)
RU (1) RU2007116973A (enExample)
WO (1) WO2006041641A2 (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2369542T3 (es) * 2002-07-31 2011-12-01 Seattle Genetics, Inc. Conjugados de auristatina y su uso para tratar cáncer, una enfermedad autoinmune o una enfermedad infecciosa.
ES2605443T3 (es) 2003-11-06 2017-03-14 Seattle Genetics, Inc. Conjugados de auristatina con anticuerpos anti-HER2 o anti-CD22 y su uso en terapia
JP2008519863A (ja) * 2004-11-12 2008-06-12 シアトル ジェネティクス インコーポレイティッド N末端にアミノ安息香酸単位を有するオーリスタチン
WO2007008848A2 (en) * 2005-07-07 2007-01-18 Seattle Genetics, Inc. Monomethylvaline compounds having phenylalanine carboxy modifications at the c-terminus
ES2708763T3 (es) 2005-07-07 2019-04-11 Seattle Genetics Inc Compuestos de monometilvalina que tienen modificaciones de la cadena lateral de fenilalanina en el extremo C
US7750116B1 (en) 2006-02-18 2010-07-06 Seattle Genetics, Inc. Antibody drug conjugate metabolites
PE20140625A1 (es) 2007-07-16 2014-05-29 Genentech Inc ANTICUERPOS ANTI-CD79b E INMUNOCONJUGADOS HUMANIZADOS
PT2474557E (pt) 2007-07-16 2014-12-03 Genentech Inc Anticorpos e imunoconjugados anti-cd79b e métodos de utilização
US20090035848A1 (en) * 2007-08-03 2009-02-05 Robert Hickey Moving bed biofilm reactor (mbbr) system for conversion of syngas components to liquid products
DK2657253T3 (en) 2008-01-31 2017-10-09 Genentech Inc Anti-CD79b antibodies and immune conjugates and methods of use
WO2009117531A1 (en) * 2008-03-18 2009-09-24 Seattle Genetics, Inc. Auristatin drug linker conjugates
WO2010054699A1 (en) * 2008-11-17 2010-05-20 Affibody Ab Conjugates of albumin binding domain
EP2513148B1 (en) 2009-12-16 2016-08-31 AbbVie Biotherapeutics Inc. Anti-her2 antibodies and their uses
SG194567A1 (en) * 2011-04-21 2013-12-30 Seattle Genetics Inc Novel binder-drug conjugates (adcs) and their use
US20140127713A1 (en) 2011-06-28 2014-05-08 Femke Karina de Theije Means for the examination of body fluids
US20130165628A1 (en) * 2011-12-23 2013-06-27 Sri International Double Binding Constructs
EP3013370A1 (en) * 2013-06-24 2016-05-04 Riogin Corporation Double binding constructs
BR112016004355A2 (pt) 2013-08-30 2017-10-17 Aprilbio Co Ltd constructo de fusão de parte efetora de fab anti-soroalbumina e método de preparação do mesmo
CA2979671C (en) 2014-09-23 2020-03-10 Genentech, Inc. Methods of using anti-cd79b immunoconjugates
CN111164104A (zh) 2017-08-09 2020-05-15 麻省理工学院 白蛋白结合肽缀合物及其方法
KR20210095781A (ko) 2020-01-24 2021-08-03 주식회사 에이프릴바이오 항원결합 단편 및 생리활성 이펙터 모이어티로 구성된 융합 컨스트럭트를 포함하는 다중결합항체 및 이를 포함하는 약학조성물
BR112022020256A2 (pt) 2020-04-09 2023-01-03 Aprilbio Co Ltd “anticorpo monoclonal ou um fragmento de ligação ao antígeno do mesmo, ácido nucleico, vetor de expressão, célula, composição, uso da composição e uso do anticorpo monoclonal ou fragmento de ligação ao antígeno do mesmo
WO2023092733A1 (zh) * 2021-11-25 2023-06-01 苏州慧疗生物医药科技有限公司 一种用于有效递送核酸的环状多肽载体及其变化形式
KR20250068754A (ko) * 2022-09-20 2025-05-16 바이오세우스 인크. 항-her2 항체 및 이의 용도

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3561444A (en) * 1968-05-22 1971-02-09 Bio Logics Inc Ultrasonic drug nebulizer
US3703173A (en) * 1970-12-31 1972-11-21 Ted A Dixon Nebulizer and tent assembly
US3862925A (en) * 1973-07-05 1975-01-28 American Home Prod Preparation of somatotropin release inhibiting factor and intermediates therefor
US3842067A (en) * 1973-07-27 1974-10-15 American Home Prod Synthesis of(des-asn5)-srif and intermediates
JPS5726506B2 (enExample) * 1974-03-08 1982-06-04
US4105603A (en) * 1977-03-28 1978-08-08 The Salk Institute For Biological Studies Peptides which effect release of hormones
US4399216A (en) * 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4624251A (en) * 1984-09-13 1986-11-25 Riker Laboratories, Inc. Apparatus for administering a nebulized substance
US4635627A (en) * 1984-09-13 1987-01-13 Riker Laboratories, Inc. Apparatus and method
US4970198A (en) * 1985-10-17 1990-11-13 American Cyanamid Company Antitumor antibiotics (LL-E33288 complex)
US5079233A (en) * 1987-01-30 1992-01-07 American Cyanamid Company N-acyl derivatives of the LL-E33288 antitumor antibiotics, composition and methods for using the same
US4975278A (en) * 1988-02-26 1990-12-04 Bristol-Myers Company Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells
US5606040A (en) * 1987-10-30 1997-02-25 American Cyanamid Company Antitumor and antibacterial substituted disulfide derivatives prepared from compounds possessing a methyl-trithio group
WO1989006692A1 (en) * 1988-01-12 1989-07-27 Genentech, Inc. Method of treating tumor cells by inhibiting growth factor receptor function
US5720937A (en) * 1988-01-12 1998-02-24 Genentech, Inc. In vivo tumor detection assay
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
SE509359C2 (sv) * 1989-08-01 1999-01-18 Cemu Bioteknik Ab Användning av stabiliserade protein- eller peptidkonjugat för framställning av ett läkemedel
EP0590058B1 (en) * 1991-06-14 2003-11-26 Genentech, Inc. HUMANIZED Heregulin ANTIBODy
WO1994004679A1 (en) * 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
US5679777A (en) * 1991-11-08 1997-10-21 Somatogen, Inc. Hemoglobins as drug delivery agents
EP0731106B1 (en) * 1993-10-01 2004-11-17 Teikoku Hormone Mfg. Co., Ltd. Dolastatin derivatives
US5773001A (en) * 1994-06-03 1998-06-30 American Cyanamid Company Conjugates of methyltrithio antitumor agents and intermediates for their synthesis
US5780054A (en) * 1996-01-17 1998-07-14 University Of British Columbia Methods for increasing the circulation half-life of protein-based therapeutics
US20050287153A1 (en) * 2002-06-28 2005-12-29 Genentech, Inc. Serum albumin binding peptides for tumor targeting
US20040001827A1 (en) * 2002-06-28 2004-01-01 Dennis Mark S. Serum albumin binding peptides for tumor targeting
US20060228364A1 (en) * 1999-12-24 2006-10-12 Genentech, Inc. Serum albumin binding peptides for tumor targeting
US6632979B2 (en) * 2000-03-16 2003-10-14 Genentech, Inc. Rodent HER2 tumor model
US20040018194A1 (en) * 2000-11-28 2004-01-29 Francisco Joseph A. Recombinant anti-CD30 antibodies and uses thereof
US20050089932A1 (en) * 2001-04-26 2005-04-28 Avidia Research Institute Novel proteins with targeted binding
US20030009395A1 (en) * 2001-07-06 2003-01-09 Yu Philip Shi-Lung Method and apparatus for providing information regarding a product
EP2292273A3 (en) * 2001-10-10 2011-11-23 BioGeneriX AG Remodeling and glycoconjugation of peptides
JP2005522514A (ja) * 2002-04-10 2005-07-28 ジェネンテック・インコーポレーテッド 抗her2抗体改変体
CA2494104A1 (en) * 2002-07-31 2004-04-22 Seattle Genetics, Inc. Anti-cd20 antibody-drug conjugates for the treatment of cancer and immune disorders
US20040032828A1 (en) * 2002-08-16 2004-02-19 Cellglide Technologies Corp. Service management in cellular networks
ES2605443T3 (es) * 2003-11-06 2017-03-14 Seattle Genetics, Inc. Conjugados de auristatina con anticuerpos anti-HER2 o anti-CD22 y su uso en terapia

Similar Documents

Publication Publication Date Title
KR102486090B1 (ko) 생체 내 내성이 높은 항체 약물 결합체
JP2023071996A (ja) 多剤抗体薬物コンジュゲート
JP7798998B2 (ja) 抗体-alk5阻害剤コンジュゲートおよびその使用
RU2007116973A (ru) Терапевтические средства с пониженной токсичностью
JP2022525704A5 (enExample)
TW202203978A (zh) 電荷可變連接子
EP4087613A1 (en) Anti-slc34a2 antibodies, antibody drug conjugates, and methods of use thereof
CN111712520A (zh) 磷脂酰肌醇聚糖3抗体及其偶联物
JP2024501894A5 (enExample)
HRP20200551T1 (hr) Axl-specifični konjugati protutijelo-lijek za liječenje raka
JP2015509097A5 (enExample)
TW201709932A (zh) Cd123抗體及其共軛物
JP2013173792A (ja) 増強された薬理学的性質を有する活性物質を送達するための方法および組成物
KR20220052960A (ko) 표적화된 덴드리머 접합체
TWI845724B (zh) 用於偶聯的多肽複合物及其應用
JP2023529640A (ja) 治療用コンジュゲート
JP2024545170A5 (enExample)
JP2026000988A (ja) Alk5阻害剤複合体およびその使用
JP2024528496A (ja) ウロキナーゼ型プラスミノーゲン活性化因子受容体関連タンパク質(uparap)を標的とするヒト化抗体を含む、抗体薬物複合体
JP2020532523A (ja) 抗egfr抗体薬物コンジュゲート(adc)及びその使用
JP2024542021A (ja) ペイロードのin vivo標的化送達用のテトラジンコンジュゲート
CN109414509B (zh) 使用双特异性抗体的抗体药物偶联物平台
CN114652853B (zh) 抗il-4r抗体-药物偶联物及医药用途
CN114269388A (zh) 抗体-alk5抑制剂缀合物及其用途
JP2022544068A5 (enExample)